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Introduction
Medicinal herbs contain physiologically active principles 
that have been exploited in traditional medicine for the 
treatment of various ailments due to their anti-microbial 
properties (1,2). The antifungal and antibacterial activity 
exhibited by extracts and essential oils of medicinal plants 
is well proved (3).
Kelussia odoratissima Mozaff. (wild celery; Apiaceae) is a 
sweet-smelling, glabrous, perennial aromatic herb, which 
is traditionally consumed in Iran and grows to a height of 
120 to 200 cm. The flowers are 1-2 mm in diameter and all 
are hermaphroditic. K. odoratissima is an Iranian endemic 
plant native to Zagros (central region of Iran) (4).
Kelussia grows in April and its aerial parts are harvested 
(5,6). Flavonoids have anti-inflammatory (7), anti-
allergy (8), anti-diabetes, antihyperlipidemic and anti-
hypercholesterolemic effects (9,10) and improves spatial 
memory (11). Phthalides constitute 70% of the Kelussia 
essence with several effects: liver protection, prostaglandin 
F2α inhibition, prevention of cancer tumors, treatment 
of epilepsy and liver disorders and reduction in blood 
viscosity (5,12,13). Despite this, there are no study related 
to the antileishmanial effect of the essential oil of K. 
odoratissima, this being the focus of our study.
Leishmaniasis affects more than 12 million people in 88 
countries (14). Cutaneous leishmaniasis (CL), with 1 to 
1.5 million annual cases, is the most common form of this 
disease (15). There is no vaccine available against any form 
of leishmaniasis and chemotherapy is the only currently 
available treatment (16,17). The standard treatment for 
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Implication for health policy/practice/research/medical education:
It is possible to use the essential oil of Kelussia odoratissima instead of chemical drugs. The use of any concentration of essential oil of 
Kelussia odoratissima controlled L. major more effectively by increasing in essential oil concentration. Future research would assess 
the effect of this essential oil on the amastigote form of L. major.
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Introduction: Leishmaniasis is a zoonotic disease caused by a protozoan of the genus Leishmania. 
In this study, the effects of Kelussia odoratissima Mozaff essential oil on the promastigot form of 
Leishmania major were studied.
Methods: In this study, the effects of Kelussia odoratissima Mozaff essential oil on the promastigot 
form of Leishmania major were assessed by calculating the average number of surviving promastigots 
after exposure to different concentrations of essential oil, relative to the control Glucantime, at 
different time intervals. To achieve this, various essential oil concentrations (7.5 µl, 15 µl, 25 µl, 35.25 
µl, 50 µl) were added to parasites. Different groups in this study were kept in a 26°C incubator under 
identical conditions. 24, 48 and 72 hours after incubation, living promastigots were counted.
Results: The effect of the essential oil of Kelussia odoratissima Mozaff differed from the negative and 
positive controls and depended on the concentration: higher concentrations (35.25 µl, 50 µl) had a 
stronger effect on promastigots, causing total mortality. 
Conclusion: This study showed that Kelussia odoratissima Mozaff essential oil had effects on 
promastigot form of Leishmania major. So it might be possible to use the essential oil of Kelussia 
odoratissima instead of chemical drugs.
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CL is antimoniate, which requires long-term injections, 
and resistance is emerging, which cause high dose usage, 
resulting side effects (17,18).
The search for new, safe and inexpensive drugs to treat 
and control CL, especially anthroponotic CL, is needed. 
Conventional healers are usually cheap and sometimes 
more effective than chemical drugs (19).
In this study, the effect of the essential oil of K. odoratissima 
on promastigot form of Leishmania major was studied. 
The results obtained from this study help us to find the 
alternative natural drug instead of chemical ones.
Materials and Methods
Plant material
A wild-growing plant from Kogiluye and Buyer Ahmad 
province located in the southwest of Iran, was collected in 
April and May, 2012. The samples, which were identified 
and confirmed as K. odoratissima Mozaff, were deposited 
in the Herbarium of the Research Institute of Jahade 
Keshavarzi of Shahrekord, Iran.
Isolation of the volatile oil
20 kg from aerial parts of the plant was dried in an oven 
equipped with warm air circulation. One hundred grams 
of the air-dried material was ground and powdered. The 
powder was subjected to hydro-distillation for 3 hours 
using a Clevenger-type system. Finally, 30 ml essential 
oil extracted. The oil was kept at 2°C to 4°C in a sealed 
brown vial.
Chemical analysis of the oil
Analysis of the essential oil was performed on a Hewlett-
Packard Model 6890 GC-MS using a HP-5MS capillary 
column (30 m×0.25 mm i.d., 0.25 m film thickness). 
The injector temperature and detector temperature was 
250°C. Helium was used as the carrier gas at a flow rate of 
1.00 ml/min. The column temperature was programmed 
from 40°C to 280°C at a rate of 4°C/min. The EI mode 
was at 70 eV, while the mass spectra were recorded from 
30 to 450 m/z. Confirmation of identity was carried out 
by comparing their retention indices with the Wiley 275 
library data of the GC–MS system and with the mass 
spectra literature data (20).
Preparing the promastigot form of Leishmania major
The promastigot form of Leishmania major strain MRHO/
IR/ER/75 was prepared from department of Parasitology 
Research, University of Medical Sciences of Isfahan, Iran. 
The promastigots were transferred to RPMI 1640 medium 
and incubated at 26°C for 72 hours.
Preparing the different concentrations and control groups
After the promastigots increased in the medium, they 
were counted using a Neobar chamber (0.100 mm, Tiefe, 
Depth, Profondeur, Neubauer Improved, Precicolor, HBG, 
Germany) in which 10 µl of this medium was mixed with 
10 µl of formalin, which was used to kill the promastigots. 
150 µl of medium contained 106 promastigots. Next, 
different concentrations of K. odoratissima essential oil 
(15, 30, 50, 75 and 100 mg/ml) were prepared, to achieve 
this, various essential oil concentrations (7.5 µl, 15 µl, 25 
µl, 35.25 µl, 50 µl) were added to parasites. There was a 
negative control (no essential oil) and a positive control 
(Glucantime®, Specia, Paris, France) by mixing with sterile 
RPMI 1640 medium in different tubes. 106 promastigots 
(i.e., 150 µl of medium containing promastigots) were 
added to each tubes, as presented in Table 1. The total 
volume of all tubes was 500 µl after mixing.
Counting the number of living promastigots after the mixing
After mixing the promastigots with different 
concentrations of K. odoratissima essential oil, those 
tubes, as well as the negative and positive controls, were 
incubated in dark incubator and in 26°C for 72 hours. The 
number of living promastigots was counted at 24, 48 and 
72 hours after incubation.
Statistical analysis
The data were analyzed by one-way analysis of variance 
(ANOVA) and significant differences (P<0.05) between 
means were assessed by Tukey’s test using SPSS software 
version 19.0.
Results
Composition of essential oil
In the essential oil of K. odoratissima, the sesquiterpene 
hydrocarbons were the most abundant compounds 
(57.77%). In addition, the least quantitative percentage 
(2.7%) was belonged to monoterpene hydrocarbons. 
The major components were Z-ligustilide (34.5%), 
E-ligustilide (11.79%), 3-Z-butylidenephthalide (8.81%) 
and Dec-9-en-1-ol (5.86%).
24 and 48 hours after incubation
Effects of essential oil of Kelussia odoratissima Mozaff on 
promastigot form of Lishmania major differenced from 
Table 1. Volume of materials in each tube prepared for different concentrations of essential oil
Tubes Materials 15 mg/ml 30 mg/ml 50 mg/ml 75 mg/ml 100 mg/ml Negative control Positive control
(Glucantime)
Promastigots 150 µl 150 µl 150 µl 150 µl 150 µl 150 µl 150 µl
RPMI 1640 342.5 µl 335 µl 325 µl 314.75 µl 300 µl 350 µl 181 µl
Glucantime - - - - - - 169 µl
Essential oil 7.5 µl 15 µl 25 µl 35.25 µl 50 µl - -
Total volume 500 µl 500 µl 500 µl 500 µl 500 µl 500 µl 500 µl
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negative control and positive controls. However, there 
were no significant differences between groups with 
different concentrations of essential oil (Table 2).
72 hours after incubation
In this time decreasing in living promastigots in different 
tubes were more than past times. Same as past times, 
effect of essential oil of Kelussia odoratissima Mozaff on 
promastigot form of Lishmania major was differenced 
from negative control and positive control (Table 2).
Totally the K. odoratissima essential oil had a different 
effect on the promastigot form of L. major relative to the 
negative and positive control, but this depended on the 
essential oil concentration; higher concentrations (35.25 
µl, 50 µl) had a stronger effect on promastigots, causing 
total mortality (Table 2). In all three-time intervals, 
the use of any concentration of essential oil of Kelussia 
odoratissima controlled L. major more effectively by 
increasing in essential oil concentration (Table 2).
Discussion
The application of natural plant products for control of 
bacterial, fungal and parasitic bee and brood diseases 
has several advantages over conventional means. In the 
specialized literature resistance of bacteria to essential 
oils has not yet been documented. In addition, natural 
substances in bee products decompose rapidly, their 
quantity in honey is low and they do not have an adverse 
effect on the health of consumers (21). Although in small 
amounts, essential oils and organic acids are normally 
contained in various types of honey. According to some 
authors their use as alternative means for prevention and 
control of bee diseases guarantees ecologically clean bee 
products (22).
This study showed antileishmanial effects of Kelussia 
odoratissima Mozaff essential oil on promastigot form 
of Leishmania major. The current treatment regimens 
for leishmaniasis, which are based on chemotherapy, are 
limited and are not ideal because they are often associated 
with severe side effects (23). In a case report from 
France, successful treatment of a 10-year-old boy with 
cutaneous leishmaniasis (L. major) was reported with oral 
azithromycin (24).
Pentavalent antimonials remain the drug of choice for the 
treatment of cutaneous and mucocutaneous leishmaniasis. 
Despite its availability in health facilities, its high toxicity 
and its parenteral use are  limiting factors for the proper 
treatment of cases of CL. It should be noted that most 
of these cases occur in areas of difficult access, in rural 
areas, which complicates the parenteral application of the 
drug and monitoring of its side effects. Treatment of CL 
with the drugs currently available represents an obstacle 
to proper clinical handling of the cases of leishmaniasis, 
and efforts should be made in order to add the promising 
drugs to clinical trials and investigate the use of new 
alternative drugs (25)
Traditional alternatives to antimonials used in 
unresponsive cases are amphotericin B, which cause 
serious, toxic side-effects (26,27), and the emergence of 
drug-resistant parasites is a major problem (17). These 
limitations and factors emphasize the urgent need for new, 
inexpensive, safe and easy-to-administer substances for 
the treatment of this infectious disease, possibly through 
the form of traditional medicines which represent the 
accumulation of practices based on theories, beliefs and 
experiences of different cultures over a wide period of 
time (28).
Amphotericin B is the second drug of choice when 
antimonials fail or cannot be used. However, they are toxic 
and expensive drugs, which often require hospitalization 
for their administration (29). An alternative to the 
treatment with conventional amphotericin B is the use of 
liposomal amphotericin B, which has higher peak plasma 
levels and lower toxicity (30). 
Traditional medicines are used for the maintenance of 
health and in the prevention, diagnosis, improvement 
and treatment of illnesses (31). Based on traditional 
medicine, new drugs of herbal origins discovered 
through ethnopharmacological studies have shown 
promising results. 
Conclusion
By considering an increase in drug resistance against 
leishmania, it is possible to use the essential oil of Kelussia 
odoratissima instead of chemical drugs. The use of any 
concentration of essential oil of Kelussia odoratissima 
controlled L. major more effectively by increasing in 
essential oil concentration. Future research would assess 
the effect of this essential oil on the amastigote form of L. 
major.
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